ood morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because the time has come to dive into the fast-growing to-do list of meetings, deadlines, and the like. You knew this would happen, yes? We find the best way to cope is to grab a cup of stimulation — our choice today is pecan pie — or a bottle of water, if you prefer. So time to get cracking. Hope you have a smashing day and do stay in touch …

A Japanese health ministry panel approved the withdrawal of a fast-track designation for Merck’s (MRK) Keytruda as a gastric cancer treatment after the rival Opdivo sold by Bristol-Myers Squibb (BMY) was granted the indication, Pharma Japan tells us. Keytruda was awarded fast-track status in 2015, but after Opdivo was approved last month, the Merck drug no longer meets the novelty threshold, which is one of four eligibility criteria for fast-track designation.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy